Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs

Blood
Haiyan JiangGlenn F Pierce

Abstract

Hemophilia A, a deficiency of functional coagulation factor VIII (FVIII), is treated via protein replacement therapy. Restoring 1% to 5% of normal blood FVIII activity prevents spontaneous bleeding, making the disease an attractive gene therapy target. Previously, we have demonstrated short-term activity of a liver-specific AAV2 vector expressing canine B-domain-deleted FVIII (cFVIII) in a hemophilia canine model. Here, we report the long-term efficacy and safety of AAV-cFVIII vectors of serotypes 2, 5, 6, and 8 in both hemophilia A mice and dogs. AAV6-cFVIII and AAV8-cFVIII restored physiologic levels of plasma FVIII activity in hemophilia A mice. The improved efficacy is attributed to more efficient gene transfer in liver compared with AAV2 and AAV5. However, supraphysiologic cFVIII levels correlated with the formation of cFVIII-neutralizing antibodies in these mice. Of importance, hemophilia A dogs that received AAV2-cFVIII, AAV6-cFVIII, and AAV8-cFVIII have persistently expressed therapeutic levels of FVIII, without antibody formation or other toxicities, for more than 3 years. However, liver transduction efficiencies are similar between AAV2, AAV6, and AAV8 serotypes in hemophilia A dogs, in contrast to mice. In summary, t...Continue Reading

References

Nov 14, 1997·Neuroscience and Biobehavioral Reviews·J H McDonough, T M Shih
Apr 10, 1999·Journal of Virology·W XiaoJ M Wilson
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·W XiaoJ M Wilson
May 9, 2001·Blood·H Chao, C E Walsh
Jun 9, 2001·The New England Journal of Medicine·P M Mannucci, E G Tuddenham
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Guang-Ping GaoJames M Wilson
Sep 20, 2002·Journal of Virology·Federico MingozziRoland W Herzog
Feb 8, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jürg M SommerJ Fraser Wright
May 1, 2004·Seminars in Thrombosis and Hemostasis·Fiona E M Rawle, David Lillicrap
May 1, 2004·Seminars in Thrombosis and Hemostasis·Katherine A High
Jul 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Peiqing YeCarol H Miao
Sep 1, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lingling DuPatricia A Thistlethwaite
Sep 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael J BlankinshipJeffrey S Chamberlain
Nov 2, 2004·The Journal of Gene Medicine·Jean-Pierre LouboutinJames M Wilson
Nov 13, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Arnaud CressantJean Michel Heard
Nov 27, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bishnu DeRonald G Crystal
Dec 9, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Baodong SunDwight D Koeberl
Dec 23, 2004·Journal of Thrombosis and Haemostasis : JTH·K A LandskronerG J Jesmok
Mar 1, 2005·Nature Biotechnology·Zhong WangXiao Xiao
Jun 1, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Baodong SunDwight D Koeberl
Jun 1, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Shunsuke KawamotoMargaret D Allen

❮ Previous
Next ❯

Citations

Nov 4, 2008·Biotechnology Letters·Shen Youjin, Yin Jun
Oct 2, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Samuel L MurphyKatherine A High
Jan 8, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lingxia ChenWeidong Xiao
Apr 17, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sharon C CunninghamIan E Alexander
Mar 19, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Patricia FavaroValder R Arruda
Aug 12, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Paul E MonahanR Jude Samulski
Sep 23, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Guy L OdomJeffrey S Chamberlain
Nov 18, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Denise E SabatinoHaig H Kazazian
Jul 27, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lingxia ChenWeidong Xiao
Dec 7, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhijian WuPaul E Monahan
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yuanqing Lu, Sihong Song
Jan 2, 2010·Human Gene Therapy·Thierry Vandendriessche, Marinee K L Chuah
Jan 6, 2011·Human Gene Therapy·Peter BellJames M Wilson
Jun 8, 2012·Human Gene Therapy·Marinee K ChuahThierry VandenDriessche
Jul 27, 2010·Current Opinion in Hematology·Janka MátraiThierry VandenDriessche
Sep 24, 2010·Journal of Virology·Robert NgMavis Agbandje-McKenna
Jul 11, 2006·The Journal of Clinical Investigation·Katherine A High
Jan 6, 2009·Journal of the American Veterinary Medical Association·Marta G P CastelhanoRory J Todhunter
May 16, 2012·EMBO Molecular Medicine·Bruno Bernardes de JesusMaria A Blasco
Jun 28, 2007·Human Gene Therapy·Brad E HoffmanRoland W Herzog
Jun 26, 2010·Expert Review of Hematology·Christopher B Doering, H Trent Spencer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.